Evidence map›Paper›PMID 21434859›Full record

ReviewCurrent drug metabolism2011

PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo.

Severin Mairinger, Thomas Erker, Markus Muller, Oliver Langer

Abstract readReview
In one paragraph

Review in Current drug metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. In vivo methods for imaging blood-brain barrier function and dysfunction.European journal of nuclear medicine and molecular imaging · 2023
    Review
  5. Article
  6. Use of imaging to assess the activity of hepatic transporters.Expert opinion on drug metabolism & toxicology · 2020
    Review
  7. Article
  8. Article
  9. Tariquidar Is an Inhibitor and Not a Substrate of Human and Mouse P-glycoprotein.Drug metabolism and disposition: the biological fate of chemicals · 2016
    Article
  10. Review
  11. Regulation of ABC transporters at the blood-brain barrier.Clinical pharmacology and therapeutics · 2015
    Review
  12. Drug transporters in the central nervous system.Clinical pharmacokinetics · 2015
    Review
  13. Role of (drug) transporters in imaging in health and disease.Drug metabolism and disposition: the biological fate of chemicals · 2014
    Review
  14. Review
  15. Review
  16. Organic anion-transporting polypeptides.Current topics in membranes · 2014
    Review
  17. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
  18. Overlapping substrate and inhibitor specificity of human and murine ABCG2.Drug metabolism and disposition: the biological fate of chemicals · 2013
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Severin MairingerHealth and Environment Department, Molecular Medicine, AIT Austrian Institute of Technology GmbH, 2444 Seibersdorf, Austria.
Thomas Erker
Markus Muller
Oliver Langer
Austrian Institute of Technology · AT

Funding

Austrian Science Fund FWF F 3513
6 · The paper itself

Abstract

Adenosine triphosphate-binding cassette (ABC) transporters, such as P-glycoprotein (Pgp, ABCB1), breast cancer resistance protein (BCRP, ABCG2) and multidrug resistance-associated proteins (MRPs) are expressed in high concentrations at various physiological barriers (e.g. blood-brain barrier, blood-testis barrier, blood-tumor barrier), where they impede the tissue accumulation of various drugs by active efflux transport. Changes in ABC transporter expression and function are thought to be implicated in various diseases, such as cancer, epilepsy, Alzheimer's and Parkinson's disease. The availability of a non-invasive imaging method which allows for measuring ABC transporter function or expression in vivo would be of great clinical use in that it could facilitate the identification of those patients that would benefit from treatment with ABC transporter modulating drugs. To date three different kinds of imaging probes have been described to measure ABC transporters in vivo: i) radiolabelled transporter substrates ii) radiolabelled transporter inhibitors and iii) radiolabelled prodrugs which are enzymatically converted into transporter substrates in the organ of interest (e.g. brain). The design of new imaging probes to visualize efflux transporters is inter alia complicated by the overlapping substrate recognition pattern of different ABC transporter types. The present article will describe currently available ABC transporter radiotracers for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) and critically discuss strengths and limitations of individual probes and their potential clinical applications.

Indexed as

RadiopharmaceuticalsAnimalsATP-Binding Cassette TransportersBiological Transport, ActiveGene ExpressionHumansPharmaceutical PreparationsPositron-Emission TomographyTissue DistributionTomography, Emission-Computed, Single-PhotonATP-Binding Cassette TransportersPharmaceutical PreparationsRadiopharmaceuticals

Identifiers

PMID21434859
PMCPMC3691789
OpenAlexW2112052019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.